Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2011-06-28
2011-06-28
Lundgren, Jeffrey S. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S809000, C514S810000, C514S812000, C514S282000
Reexamination Certificate
active
07968604
ABSTRACT:
Provided is a pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder, comprising sodium phenylbutyrate (PBA). The pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder in accordance with the present invention provides effects capable of inhibiting increases in locomotor activity which is a behavioral indicator of drug or alcohol addiction or bipolar disorder, by controlling a level of a neurotransmitter via regulation of expression of a neurotransmitter transporter.
REFERENCES:
patent: 6362226 (2002-03-01), Phillips, III et al.
patent: 6372938 (2002-04-01), Burzynski et al.
patent: 2004/0242570 (2004-12-01), Nudelman et al.
patent: 2006/0018921 (2006-01-01), Levenson
patent: 2006/0045912 (2006-03-01), Truog
patent: 02090534 (2002-11-01), None
Vonk, Ronald, et al, “Is Autoimmune Thyroiditis Part of the Genetic Vulnerability (or an Endophenotype) for Bipolar Disorder,” Biol. Psychiatry, vol. 62, pp. 135-140 (2007).
Nurco, David N., et al, “Differential Contributions of Family and Peer Factors to the Etiology of Narcotic Addiction,” Drug and Alcohol Dependence, vol. 51, pp. 229-237 (1998).
Core et al., “Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells,” Clinical Cancer Research Oct. 1997 3; 1755.
Fibach et al, “Enhanced fetal hemoglobin production by phenylacetate and 4- phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia,” vol. 82, Issue 7, pp. 2203-2209, Oct. 1, 1993.
Kruh, J., Effects of sodium butyrate, a new pharmacological agent, on cells in culture; Molecular and Cellular Biochemistry 42, 65-82 (1982).
Prasad, K. N., Butyric Acid: a small fatty acid with diverse biological functions; Life Sciences. vol. 27, 1351-1358 (1980).
The extended European Search Report by the European Patent Office, issued on Aug. 31, 2010, in the European patent application No. 06798579.6.
Phiel et al., “Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen,” J. Biol. Chem. Sep. 28, 2001;276(39):36734-41.
Gurvich et al., “Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation,” Cancer Res Feb. 1, 2004 64; 1079.
Kang et al., “Life extension in Drosophila by feeding a drug,” Proc Nati Acad Sci U S A. Jan. 22, 2002;99(2):838-43.
Ralph et al., “Valproate Attenuates Hyperactive and Perseverative Locomotor Behaviors in Dopamine Transporter Knockdown Mice,” Society for Neuroscience Abstract, vol. 27, No. 1, 2001, p. 1432.
Chen et al., “Evidence for the Involvement of Extracellular Signal-regulated Kinase (ERK) Pathway in Mood Modulation,” Society for Neuroscience Abstract Viewer and Itinerary Planner, vol. 2002, 2002, XP8125900.
Tomasiewicz et al., “Behavioral effects of short-term administration of lithium and valproic acid in rats,” Brain Res. Jun. 6, 2006;1093(1):83-94. Epub May 9, 2006. XP8125908.
International Search Report and Written Opinion dated Nov. 21, 2006.
Burlina, A.B. et al., Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Molecul. Genet. Metab. 2001, vol. 72, pp. 351-355.
Resar, L.M. et al., Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy, J. Pediatr. Hematol. Oncol. 2002, vol. 24, No. 9, pp. 737-741.
Zhang, X. et al. Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J. Cell. Biochem. 2004, vol. 93, No. 4, pp. 819-829 (2004).
Kim, Jeong-Hoon. et al. The metabotropic glutamate receptor antagonist (RS)-MCPG produces hyperlocomotion in amphetamine pre-exposed rats. Neuropharmacology 37, (1998) 189-197.
Ferguson, Sally A.et al. Prenatal exposure to the dopamine agonist SKF-3893 disrupts the timing of the initial response of the suprachiasmatic nucleus to light. Brain Research 858 (2000) 284-289.
Zavala, A.R., et al., Cocaine-induced behavioral sensitization in the young rat. Psychopharmacology (2000) 151:291-298.
Karler, Ralph, et al., Amphetamine behavioral sensitization and the excitatory amino acids. Brain Research, 537 (1990) 76-82 Elsevier.
Einhorn, Leslie C., et al. Electrophysiological Effects of Cocoaine in the Mesoaccumbens Dopamine System: Studies in the Ventral Tegmental Area. The Journal of Neuroscience, Jan. 1988, 8(1):100-112.
Dismukes, Key, et al., Efffects of Neuroleptics on Release of 3H-Dopamine from Slices of Rat Corpus striatum. Naunyn-Schmiedeberg's Arch. Pharmacol. 297, 23-29 (1977).
Robertson, H.A., Expression of the Immediate Early Gene f-fos in Basal Ganglia: Induction by Dopaminergic Drugs. Canadian Journal of Neurological Sciences. 1991, 18:380-383.
Kuczenski, Ronald, et al. Amphetamine, Cocaine, and Fencamfamine: Relationship between Locomotor and Stereotypy Response Profiles and Caudate and Accumbens Dopamine Dynamics. The Journal of Neuroscience, Sep. 1991, 11(9):2703-2712.
Pontieri, F.E., et al., Intraveneous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as copared with the “core” of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA vol. 92, pp. 12304-12308, Dec. 1995 Pharmacology.
Belmaker, R. H. MD., Medical Progress Bipolar Disorder. N Engl J. Med 351:5, Jul. 29, 2004. pp. 476-486.
Kupfer, David J. MD., The Increasing Medical Burden in Bipolar Disorder. JAMA, May 25, 2005-vol. 293, No. 20 (Reprinted).
Frey, Benicio N., et al., Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 79 (2006) 281-286.
Arban, Roberto, et al., Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behavioural Brain Research 158 (2005) 123-132.
Dackis, Charles, A., Clinical Implications of Cocaine-Induced Cortical Depression. Neuropsychopharmacology (2005) 30, 1033.
Spanagel, Rainer, et al., The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nature Medicine vol. 11, No. 1, Jan. 2005, pp. 35-42.
McClung, Colleen A., Regulation of dopaminergic transmission and cocaine reward by the Clock gene. PNAS, Jun. 28, 2005. vol. 102, No. 26, pp. 9377-9381.
Kenna, George A., Pharmacotherapy of alcohol dependence: Targeting a complex disorder. vol. 2. No. 1, 2005, pp. 71-78.
Herman, Barbara H., et al. Medications for the treatment of cocaine addiction: Emerging candidates. vol. 2. No. 1, 2005, pp. 87-92.
Cho Jeong-Woo
Choi Sang-Rak
Hwang Sun-Gwan
Lundgren Jeffrey S.
Rao Savitha
LandOfFree
Pharmaceutical composition for prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2669293